Source: Datametrex AI.
  • Datametrex (DM) telehealth subsidiary, Medi-Call, has introduced virtual mental health services to subscribers in Vancouver
  • Datametrex will adapt its Nexalogy, AI technology with Medi-Call’s App to help detect mental health issues through social posting
  • Three physicians have recently joined the Medi-Call team
  • Medi-Call is a subscription-based software as a service (SaaS) mobile application that connects patients with doctors
  • Datametrex AI Ltd is a Canada-based information technology company
  • Datametrex AI Limited (DM) opened trading at C$0.115

Datametrex AI (DM) telehealth subsidiary, Medi-Call, has introduced virtual mental health services to subscribers in Vancouver.

With virtual counselling, support, medical attention and prescription services, patients can get the help they need virtually.

The company advocates for mental health awareness and plans to provide accessible mental health services for those in need. Datametrex plans to adapt its Nexalogy, AI technology with Medi-Call’s App to help detect mental health issues through social posting and provide services and solutions through its AI integrated software.

According to the latest mental health data, patient comfort with virtual behavioural healthcare is high across all age groups. Among Baby Boomers, 45 percent said they are comfortable with virtual care for mental health. 55 percent of Generation X said they were equally comfortable with virtual mental care, while 15 percent said they were more comfortable with receiving mental health care virtually, than in-person.

With a high volume of patients adapting to virtual healthcare and a rising margin for more people open to mental health care in the virtual space, Datametrex believes adding this service will be a beneficial service for all.

The World Health Organization states that the COVID-19 pandemic triggered a 25 percent increase of anxiety and depression worldwide and urges all countries to step up their mental health services and support, which is why Medi-Call is dedicated to providing more accessible mental healthcare to Canadians.

Three physicians have recently joined the Medi-Call team. Dr. Vincent Fung, Dr. Reem Habtezion and Dr. Dale Raj Dhillon joined Dr. Omar Sharif, advancing Medi-Call further into the healthcare and telehealth space.

Marshall Gunter, CEO of Datametrex, commented on the news.

“We are thrilled to be expanding Medi-Call by adding new mental health services and adding more physicians to the team. We expect Medi-Call to continue to gain traction. Ensuring we are staffed sufficiently is a priority, so patients’ needs are met.”

Dr. Omar Sharif, Datametrex’s Chief Medical Officer, added,

“According to the latest Canadian statistics, the mental health crisis continues to plague Canadians at an alarming rate. Some groups in particular include our youth, minorities and the elderly. In addition, those reporting poor mental health are 400% more likely to report increased substance use since before the pandemic. We believe that our robust practitioners and accelerated access to care will help to combat this problem.”

Medi-Call is a subscription-based software as a service (SaaS) mobile application that connects patients with doctors. Medi-Call solves accessibility issues for patients living in rural or isolated communities and those also have limited mobility while improving coordination and communication of treatment among healthcare team members and their patients.

Datametrex AI Limited is a technology-focused company with exposure to artificial intelligence, machine learning, telehealth and has recently entered the electric vehicle (EV) market.

Datametrex AI Limited (DM) opened trading at C$0.115.


More From The Market Online

BlackBerry expands AI-powered cybersecurity service

BlackBerry (TSX:BB) releases the new and expanded CylanceMDR, a managed detection and response tool backed by its Cylance AI platform.

Qualcomm stock jumps on Q2 2024 earnings

Qualcomm (NDAQ:QCOM) shares rise nearly 10 per cent early Thursday on better-than-expected adjusted earnings and strong revenue guidance.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

Fobi AI could address a market in the trillions: Why it’s time to buy

Fobi AI (TSXV:FOBI) is an essential stock to consider to capitalize on the exponential trends of digital wallets and artificial intelligence.